



Announcement Summary

Entity name

IMUGENE LIMITED

Announcement Type

New announcement

Date of this announcement

7/7/2026

The Proposed issue is:

A placement or other type of issue

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
IMU	ORDINARY FULLY PAID	117,052,638

Proposed +issue date

13/7/2026

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of +Entity

IMUGENE LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).

1.2 Registered Number Type

ABN

Registration Number

99009179551

1.3 ASX issuer code

IMU

1.4 The announcement is

New announcement

1.5 Date of this announcement

7/7/2026

1.6 The Proposed issue is:

A placement or other type of issue



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?

Yes

7A.1a Conditions

Approval/Condition	Date for determination	Is the date estimated or actual?	** Approval received/condition met?
+Security holder approval	18/8/2026	Estimated	

Comments

Tranche 1: Approximately 73.7 million fully paid ordinary shares to be issued to institutional and sophisticated investors, utilising the Company's available placement capacity under ASX Listing Rules 7.1 and 7.1A.

Tranche 2: Approximately 43.4 million fully paid ordinary shares to be issued to certain investors, including Directors. The issue of shares to Directors and to certain investors, is subject to shareholder approval at an extraordinary general meeting.

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)?
Existing class

Will the proposed issue of this +security include an offer of attaching +securities?
No

Details of +securities proposed to be issued

ASX +security code and description

IMU : ORDINARY FULLY PAID

Number of +securities proposed to be issued

117,052,638

Offer price details

Are the +securities proposed to be issued being issued for a cash consideration?
Yes

In what currency is the cash consideration being paid?

AUD - Australian Dollar

What is the issue price per +security?

AUD 0.09500



Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Part 7C - Timetable

7C.1 Proposed +issue date

13/7/2026

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1?

No

7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Issuance of approximately 63,312,756 million New Shares, as part of Tranche 1 Placement pursuant to the Company placement capacity under Listing Rules 7.1.

7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

Yes

7D.1c (i) How many +securities are proposed to be issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A?

Issuance of approximately 10,371,459 million New Shares, as part of Tranche 1 Placement pursuant to the Company placement capacity under Listing Rules 7.1.A.

7D.1c (ii) Please explain why the entity has chosen to do a placement rather than a +pro rata issue or an offer under a +security purchase plan in which existing ordinary +security holders would have been eligible to participate

The placement enables the Company to access institutional and sophisticated investors quickly, minimise execution risk and transaction costs. The Board considers the placement to be in the best interests of the Company and its shareholders in the circumstances.

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?

Yes

7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?

No

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow?

No

Part 7E - Fees and expenses

7E.1 Will there be a lead manager or broker to the proposed issue?

Yes



7E.1a Who is the lead manager/broker?

Bell Potter Securities Limited acted as Lead Manager and Bookrunner to the Placement.

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

A management fee of 0.75% of total proceeds raised globally and 5.25% of total proceeds raised in the placement from Australia, New Zealand and Asia Investors.

7E.2 Is the proposed issue to be underwritten?

No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue

The total estimated expenses of the Offer payable by the Company including ASX fees, accounting fees, legal fees, share registry fees, printing costs, public relations costs and other miscellaneous expenses are estimated to be \$0.8 million.

Part 7F - Further Information

7F.01 The purpose(s) for which the entity is issuing the securities

Proceeds of the Offer will be used to advance the Company's lead asset, azer-cel, through key clinical, regulatory and manufacturing milestones, and for general working capital purposes.

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds?

No

7F.2 Any other information the entity wishes to provide about the proposed issue

7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)